Wells Fargo sees more downside than upside, starts Danaher with Equal Weight

As previously reported, Wells Fargo initiated coverage of Danaher with an Equal Weight rating and $280 price target. The firm is positively biased toward Danaher’s high-quality portfolio and exposure to the bioprocess recovery theme. That said, Wells sees more downside than upside risk to 2025 consensus expectations and with valuation at a premium, stays on the sidelines.